Pittsburgh, Pa., USA - July 29, 2009, Pittsburgh, Pa., USA - Mylan Inc., a diversified generics and specialty pharmaceutical company, announced several key enhancements to its executive management team.
Article continues below
Heather Bresch has been promoted to president. In this expanded executive leadership role, Bresch will take on additional leadership responsibilities related to the day-to-day operations of the company. She served most recently as Mylan's chief operating officer.
Throughout her 17-year tenure with the company, Ms. Bresch has performed with distinction and as chief integration officer was instrumental in overseeing Mylan's transformation into one of the world's largest and most efficient generics and specialty pharmaceutical companies.
Other executive positions previously held by Ms. Bresch include senior vice president of Strategic Corporate Development and head of North American Operations.
Rajiv Malik has been promoted to chief operating officer.
Most recently, Mr. Malik was head of Mylan's global technical operations, where he oversaw R&D and manufacturing; supply chain and sourcing; and quality and regulatory affairs.
He will continue to be responsible for these areas and also oversee the company's generic biologics efforts as well as those initiatives related to emerging markets.
Mr. Malik's contributions were also instrumental to the integration of both Matrix and the former Merck Generics businesses and in helping Mylan to become one of world's largest, quality pharmaceutical companies.
Prior to Mylan, Mr. Malik has more than 25 years of global generic pharmaceutical industry experience in leadership positions, including most recently as CEO of Matrix.
Timothy B. Sawyer has joined Mylan as senior vice president of Strategic Corporate Development.
Mr. Sawyer enjoys an exemplary 16-year track record in the generic pharmaceutical industry, primarily in commercial operations.
Mr. Sawyer joins Mylan from Teva Pharmaceuticals, where he served most recently as executive vice president, Global Generic Sales and Marketing, for Barr Laboratories, whose parent company, Barr Pharmaceuticals, was acquired by Teva.
In that position, Mr. Sawyer was responsible for all generic marketing and sales in North America as well as commercial activities in the rest of the world.
Mr. Sawyer also led the successful integration of Barr's ex-U.S. commercial operations following its 2006 acquisition of Croatia-based PLIVA. ■